DGS Capital Management LLC Buys 385 Shares of Sanofi (NASDAQ:SNY)

DGS Capital Management LLC raised its stake in Sanofi (NASDAQ:SNY) by 4.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,623 shares of the company’s stock after buying an additional 385 shares during the period. DGS Capital Management LLC’s holdings in Sanofi were worth $555,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Bank of New York Mellon Corp grew its position in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Franklin Resources Inc. boosted its stake in Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares during the period. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $46.80 on Friday. The company has a fifty day moving average price of $51.02 and a 200-day moving average price of $52.04. The firm has a market cap of $118.77 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the firm posted $2.55 EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.